Synuclein PET project

As the Parkinson’s field starts to solve the problem of how to detect toxic α-synuclein in the brain, it’s closing in on imaging agents that could de-risk clinical trials. Phase I data expected this year could give a glimpse of whether new PET agents are up to the job, avoiding the poor selectivity that has thwarted the tools’ success so far.

The hope is that an α-synuclein PET agent could provide drug developers with a molecular diagnostic and a biomarker of therapeutic response for the disease. ...